Skip to main content
Clinical Trials/NCT06626802
NCT06626802
Completed
Not Applicable

Intralesional Steroid Injection Versus Topical Mitomycin-C Use in Pediatric Benign Recurrent Esophageal Stricture: A Randomized Control Trial

King Edward Medical University1 site in 1 country24 target enrollmentJuly 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Esophageal Stricture
Sponsor
King Edward Medical University
Enrollment
24
Locations
1
Primary Endpoint
Effectiveness measured in terms of improvement in Dysphagia Severity Score (DSS)
Status
Completed
Last Updated
last year

Overview

Brief Summary

To compare the efficacy of steroid injection versus topical mitomycin-C in the treatment of pediatric benign recurrent esophageal strictures. The rationale for this study is to compare the two therapeutic options in order to measure their effectiveness, in terms of improvement of Dysphagia Severity Score (DSS).

Detailed Description

After taking approval from the Institutional Review Board of the university; and taking the informed consent from parents, patients fulfilling the inclusion and exclusion criteria will be enrolled in the study. They will be then randomly allocated into two groups; group A and group B. Patients in Group A will be treated with esophageal dilation with a CRE balloon (controlled radial expansion balloon). After adequate dilation of stricture, injection Mitomycin will be applied to the narrowest portion of the stricture. Patients in Group B will be treated with esophageal dilation with a CRE balloon in the same manner. After adequate dilation of stricture, Triamcinolone injection will be injected into the narrowest portion of the stricture, using a sclerotherapy injector. Dysphagia Severity Score will be noted at start of intervention, at 2 weeks after intervention and at 6 weeks post- intervention.

Registry
clinicaltrials.gov
Start Date
July 1, 2023
End Date
June 30, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Tehreem Fatima

Senior Registrar

King Edward Medical University

Eligibility Criteria

Inclusion Criteria

  • Patients up to 16 years of age belonging to both genders
  • Patients with single esophageal stricture
  • Patients with benign recurrent esophageal strictures
  • Patients with any etiology for esophageal stricture including; post-corrosive, congenital, post-anastomotic and eosinophilic.

Exclusion Criteria

  • Patients unfit for anesthesia and/or hemodynamic instability
  • Patients with hemostatic disorder (platelets \<50,000 or international normalized ratio \>1.5)
  • Patients who have undergone esophageal surgery in last one month
  • Patients with complications such as; stricture perforation, signs of air leak or mediastinitis
  • Those with hypersensitivity to Mitomycin- C
  • Patients with multiple strictures

Outcomes

Primary Outcomes

Effectiveness measured in terms of improvement in Dysphagia Severity Score (DSS)

Time Frame: 6 weeks

Patients in both groups (group A and group B) will be followed and mean dysphagia severity score will be noted at 0, 2 and 6 weeks of intervention in both the groups. Improvement in dysphagia will be monitored via a validated Dysphagia Severity Score (DSS). It is as follows: 0 Able to eat normal diet/no dysphagia 1. Able to swallow some solid foods 2. Able to swallow only semi solid foods 3. Able to swallow liquids only 4. Unable to swallow anything/total dysphagia

Study Sites (1)

Loading locations...

Similar Trials